Elagolix

Drug Profile

Elagolix

Alternative Names: ABT-620; Elagolix sodium; NBI-56418

Latest Information Update: 01 Feb 2017

Price : $50

At a glance

  • Originator Icahn School of Medicine at Mount Sinai
  • Developer AbbVie; Neurocrine Biosciences
  • Class Antineoplastics; Fluorinated hydrocarbons; Pyrimidines; Small molecules
  • Mechanism of Action LHRH receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Endometriosis; Uterine leiomyoma
  • Discontinued Benign prostatic hyperplasia; Prostate cancer

Most Recent Events

  • 01 Dec 2016 AbbVie completes a phase III trial in Endometriosis in USA, Argentina, Australia, Austria, Brazil, Czech Republic, Hungary, Italy, New Zealand, Poland, South Africa, Spain and United Kingdom (PO) (NCT01931670)
  • 19 Oct 2016 Adverse events and efficacy data from two replicate phase III trials (M12-665 and M12-671) in Endometriosis released by AbbVie
  • 01 Sep 2016 AbbVie initiates a phase III extension trial for Uterine leiomyoma (NCT02925494)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top